



## Threshold Pharmaceuticals ASCO Webcast Available On Company Website

REDWOOD CITY, Calif., Jun 8, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that a webcast of the Company's ASCO investor presentation is now available on the Company's website. The webcast, which was not available immediately due to technical difficulties, can be accessed on the Investor page of the Company's website. <http://investor.thresholdpharm.com/events.cfm>

The webcast presentation covers clinical trial results related to its clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the American Society for Clinical Oncology (ASCO) on May 31, 2009.

### About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ([www.thresholdpharm.com](http://www.thresholdpharm.com)).

### Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial results and plans, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 7, 2009 and is available from the SEC's website ([www.sec.gov](http://www.sec.gov)) and on our website ([www.thresholdpharm.com](http://www.thresholdpharm.com)) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

This news release was distributed by GlobeNewswire, [www.globenewswire.com](http://www.globenewswire.com)

SOURCE: Threshold Pharmaceuticals, Inc.

Threshold Pharmaceuticals, Inc.

Denise T. Powell, Sr. Director, Corporate Communications  
650-474-8206

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX